List of Contents

Red Biotechnology Market Size, Share, and Trends 2024 to 2034

Red Biotechnology Market (By Product Type: Gene Recombinant Drugs, Human Vaccines, Blood Products Diagnostics Reagents Personalized Medicines, Others; By Application: Pharmacogenomics, Gene Therapy, Genetic Testing and Biopharmaceutical Production; By End-User: Research Institutes, CMOs & CROs, Biopharmaceutical Industries, Others) - Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2024 - 2033

  • Last Updated : February 2024
  • Report Code : 1010
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Red Biotechnology Market 

5.1. COVID-19 Landscape: Red Biotechnology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Red Biotechnology Market, By Product

8.1. Red Biotechnology Market, by Product Type, 2024-2033

8.1.1. Gene Recombinant Drugs

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Human Vaccines

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Blood Products

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Personalized Medicines

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Diagnostics Reagents

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Red Biotechnology Market, By Application

9.1. Red Biotechnology Market, by Application, 2024-2033

9.1.1. Pharmacogenomics

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Biopharmaceutical Production

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Gene Therapy

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Genetic Testing

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Red Biotechnology Market, By End User 

10.1. Red Biotechnology Market, by End User, 2024-2033

10.1.1. Research Institutes

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. CMOs & CROs

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Biopharmaceutical Industries

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Red Biotechnology Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by End User (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End User (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End User (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End User (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End User (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End User (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End User (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Forecast, by End User (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End User (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End User (2021-2033)

Chapter 12. Company Profiles

12.1. Hoffmann-La Roche, Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Merck KGaA

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Regeneron Pharmaceuticals, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Pfizer, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Biogen Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Amgen Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca Plc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Takeda Pharmaceutical Company Ltd.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Gilead Sciences, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. CELGENE CORPORATION

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

 

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The red biotechnology market size was reached at USD 385.01 billion in 2023 and is anticipated to hit USD 649.31 billion by 2033.

Growing occurrence of rare and chronic illness worldwide is foreseen to propel growth of red biotechnology market in the coming years.

Red biotechnology is a division of biotechnology that studies human health care and approaches of treatment by improvement of medicines such as antibiotics.

The global red biotechnology market is growing at a noteworthy CAGR of 5.36% over forecast period 2024 to 2033.

Geographically, North America is occupied major chunk of the revenue of global red biotechnology market.

The top key companies are contributing in the red biotechnology market are Hoffmann-La Roche, Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Pfizer, Inc. , Biogen Inc. , Amgen Inc. and AstraZeneca Plc. and etc.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us